지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.9
- 수록면
- 486 - 498 (13page)
- DOI
- https://doi.org/10.4111/icu.20220103
이용수
초록· 키워드
오류제보하기
In the clinical setting of renal cell carcinoma (RCC), immune reactions such as tumor-specific T cell responses can be spontaneous events or can be elicited by checkpoint inhibitors, cytokines, and other immunotherapy modalities. The results from immunotherapy have led to significant advances in treatment methods and patient outcomes. The approval of nivolumab primarily as a second-line monotherapy and the latest approval of novel combination therapies as first-line treatment have established the significance of immunotherapy in the treatment of RCC. In this perspective, chimeric antigen receptor (CAR)-T cell therapy represents a major advance in the developing field of immunotherapy. This treatment modality facilitates T cells to express specific CARs on the cell surface which are reinfused to the patient to treat the analogous tumor cells. After showing treatment potential in hematological malignancies, this new therapeutic approach has become a strong candidate as a therapeutic modality for solid neoplasms. Although CAR-T cell therapy has shown promise and clinical benefit compared to previous T-cell modulated immunotherapies, further studies are warranted to overcome unfavorable physiological settings and hindrances such as the lack of specific molecular targets, depletion of CAR-T cells, a hostile tumor microenvironment, and on/off-tumor toxicities. Several approaches are being considered and research is ongoing to overcome these problems. In this comprehensive review, we provide the rationale and preliminary results of CAR-T cell therapy in RCC and discuss emerging novel strategies and future directions.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Practical issues in CAR T-cell therapy
Blood Research
2023 .04
-
CAR-T 세포 치료제
대한내과학회지
2022 .08
-
Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
Annals of Laboratory Medicine
2024 .05
-
CAR T Cell Immunotherapy Beyond Haematological Malignancy
Immune Network
2022 .02
-
Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation
전남의대학술지
2020 .01
-
광범위큰B세포림프종에 대한 키메릭항원수용체T세포 (Chimeric Antigen Receptor T-cells) 치료
대한내과학회지
2019 .04
-
Novel immunotherapy in metastatic renal cell carcinoma
Investigative and Clinical Urology
2017 .01
-
Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
-
Tumor immune response and immunotherapy in gastric cancer
Journal of Pathology and Translational Medicine
2020 .01
-
Evolution of CAR-T Cell Therapy
대한외과학회 학술대회 초록집
2019 .10
-
An update on immunotherapy with PD-1 and PD-L1 blockade
Journal of Yeungnam Medical Science
2021 .10
-
Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy
Immune Network
2022 .02
-
Immuno-oncology for B-cell lymphomas
Blood Research
2021 .01
-
Immuno-oncology for B-cell lymphomas
Blood Research
2021 .04
-
Immunotherapy in Pediatric Solid Tumors
Clinical Pediatric Hematology-Oncology
2020 .01
-
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46
Immune Network
2024 .10
-
NK Cell-Based Immunotherapies in Cancer
Immune Network
2020 .04
-
Emerging Biomaterials for Tumor Immunotherapy
생체재료학회지
2023 .03
-
Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
Blood Research
2023 .04
-
Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells
Immune Network
2016 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0